Skip to main content
. 2019 Jul 12;20:578. doi: 10.1186/s12864-019-5929-1

Table 2.

The presence of biofilm-related genes for each agr group

Agr group (%)
Biofilm Plate Titer (N = 248) AgrI AgrII AgrIII AgrIV NT SarA gene
 Weak biofilm producer (n = 81, 32.7%) 30.6 17.4 43.9 66.7 13.9 77.7
 Modertae biofilm producer (n = 115, 46.3%) 42.9 56.5 50.0 22.2 47.2 73.9
 Strong biofilm producer (n = 52, 20.9%) 26.5 26.1 6.1 11.1 38.9 48.1
 Total (n, %) (98, 39.5%) (23, 9.3%) (82, 33.1%) (9, 3.6%) (36, 14.5%) 173
SarA gene (173, 69.7%) 80.6 65.2 80.5 77.7 16.6
Adhesion Genes
 icaD/ icaA(n = 248) 87.7 87.0 78.0 88.9 80.6 58.5
 Eno (n = 235, 94.8%) 92.9 91.3 97.6 100.0 94.4 71.5
 ClfA (n = 199, 80.2%) 92.9 87.0 89.0 55.6 27.8 80.4
 ClfB (n = 199, 80.2%) 92.9 87.0 89.0 55.6 27.8 80.4
 FnbA (n = 194, 78.2%) 87.8 78.3 91.5 66.7 25.0 81.4
 EbpS (n = 191, 76.2%) 82.7 60.9 84.1 55.6 55.6 76.4
 Fib (n = 154, 62.2%) 60.2 73.9 80.5 66.7 16.7 83.1
 Cna (n = 99, 39.9%) 46.9 21.7 53.7 0.0 11.1 78.8
 FnbB (n = 72, 29.0%) 52.0 21.7 13.4 11.1 11.1 81.9
Antibiotic Resistance
 Cefoxitin/Penicillin (n = 248) 100.0 100.0 100.0 100.0 100.0 100
 Erythromycin (n = 163) 59.2 60.9 69.5 33.3 86.1 63.2
 Ciprofloxacin (n = 109) 58.2 56.5 20.7 33.3 52.8 63.3
 Clindamycin (n = 95) 28.6 43.5 48.8 11.1 44.4 65.3
 Gentamycin (n = 58) 27.6 21.7 11.0 22.2 41.7 55.2
 SXT (n = 55) 19.4 21.7 11.0 11.1 58.3 41.8
 MDR (n = 66) 22.4 43.5 13.4 11.1 61.1 46.9
Source of isolate
 Wound (n = 78) 36.7 34.8 35.4 22.2 8.3 80.7
 Blood (n = 34) 11.2 17.4 11.0 11.1 25.0 52.9
 Nasal (n = 25) 11.2 13.0 8.5 0.0 11.1 64
 Pus (n = 23) 8.2 8.7 13.4 22.2 0.0 95.6
 Urine (n = 23) 1.0 0.0 11.0 22.2 30.6 43.5
 Tissue (n = 13) 9.2 8.7 2.4 0.0 0.0 61.5
 Sputum (n = 12) 3.1 8.7 6.1 0.0 5.6 58.3
 Other sites (n = 40) 19.4 8.7 12.2 22.2 19.4 72.5